NCT05568706 (RSVHR) is a Phase 2 clinical trial of EDP-938 in RSV Infection, sponsored by Enanta Pharmaceuticals, Inc.

Who is sponsoring NCT05568706?

NCT05568706 is sponsored by Enanta Pharmaceuticals, Inc.

What drugs are being tested in NCT05568706?

Interventions in NCT05568706: EDP-938, Placebo.

What condition does NCT05568706 study?

NCT05568706 studies RSV Infection.

Is NCT05568706 still recruiting?

NCT05568706 is currently completed. Last updated 1 July 2025.

Last reviewed 2025-07-01 · How we verify

NCT05568706: RSVHR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

Completed Phase 2 Last updated 1 July 2025

What this trial tests

Phase 2 trial testing EDP-938 in RSV Infection in 186 participants. Completed in 23 June 2025.

Timeline

29 November 2022

Primary endpoint
23 June 2025

23 June 2025

Quick facts

Lead sponsor	Enanta Pharmaceuticals, Inc
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	186
Start date	29 November 2022
Primary completion	23 June 2025
Estimated completion	23 June 2025
Sites	84 locations across Colombia, Slovakia, South Africa, Malaysia, Taiwan, Poland, Mexico, Argentina

Drugs / interventions tested

EDP-938 — full drug profile →
Placebo

Conditions studied

RSV Infection — all drugs for RSV Infection →

Sponsor

Enanta Pharmaceuticals, Inc — full company profile →

Who can join

18 and older, any sex, with RSV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who are at high risk for complications after RSV infection.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Landscape of respiratory syncytial virus.
Duan Y, Liu Z, Zang N, Cong B, et al · · 2024 · cited 17× · PMID 39501814 · DOI 10.1097/cm9.0000000000003354
Current antiviral therapies and promising drug candidates against respiratory syncytial virus infection.
Feng Z, Xie Z, Xu L. · · 2025 · cited 5× · PMID 39884359 · DOI 10.1016/j.virs.2025.01.003
EDP-938 Has a High Barrier to Resistance in Healthy Adults Experimentally Infected with Respiratory Syncytial Virus.
Levene RE, DeVincenzo J, Conery AL, Ahmad A, et al · · 2025 · cited 5× · PMID 39441691 · DOI 10.1093/infdis/jiae471

Verify or expand the search:

Other trials of EDP-938

Trials testing the same drug.

NCT04816721 — A Study to Evaluate EDP 938 Regimens in Children With RSV · Phase 2 · completed
NCT04633187 — Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Re · Phase 2 · terminated
NCT04927793 — Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Male Subjects · Phase 1 · completed
NCT04871724 — Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects · Phase 1 · completed
NCT04498741 — Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects · Phase 1 · completed

Other recruiting trials for RSV Infection

Currently open trials in the same condition.

NCT06881953 — Prevention Strategy for Respiratory Syncytial Virus (RSV) Infections in Infants in France · recruiting
NCT06866405 — A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Sin · Phase 3 · recruiting
NCT06843317 — Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults · Phase 1 · recruiting
NCT06172660 — Real-World Effectiveness of Perinatal RSV Immunoprophylaxis · recruiting
NCT06640387 — CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools · recruiting

Other Enanta Pharmaceuticals, Inc trials

Trials by the same sponsor.

NCT06917508 — A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participa · Phase 1 · completed
NCT06847464 — A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the P · Phase 1 · completed
NCT06601192 — A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults · Phase 1 · completed
NCT06170242 — A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus · Phase 2 · completed
NCT05616728 — A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19 · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05568706 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Enanta Pharmaceuticals, Inc
Last refreshed: 1 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05568706.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing